Road Back Foundation Files Ethics Complaint and Requests Retraction of Mayes et al. (2004) Scleroderma Trial
A call for scientific integrity, transparency, and correction of the medical record
The Road Back Foundation (RBF) has formally filed an ethics complaint and submitted a request for retraction and correction regarding the 2004 Arthritis & Rheumatology clinical trial, “Minocycline in Systemic Sclerosis” (Mayes et al.).
This action follows an extensive, data-driven review of the published study, its stated outcome measures, and the actual clinical results reported within the paper.
At issue is not a difference of opinion, but a clear and consequential disconnect between the study’s predefined success criteria and the authors’ conclusions, which continue to influence clinical practice, guidelines, and patient access to therapy more than two decades later.
Background: Why the 2004 Mayes Study Matters
Systemic sclerosis (scleroderma) is a rare, serious autoimmune disease associated with significant morbidity and mortality. In the early 2000s, minocycline—a tetracycline antibiotic with known immunomodulatory and anti-fibrotic properties—was being investigated as a potential disease-modifying therapy.
The Mayes et al. trial became the most frequently cited study used to dismiss minocycline as ineffective in systemic sclerosis. Its conclusions have been repeatedly referenced in clinical discussions, reviews, and guidelines to justify excluding antibiotic-based therapy from consideration.
Because of this outsized influence, accuracy and faithful reporting of results are essential.
The Predefined Success Criterion: ≥30% Improvement in MRSS
In the published methods section, the authors defined clinical success using the Modified Rodnan Skin Score (MRSS)—a validated and widely accepted measure of skin involvement and disease severity in systemic sclerosis.
The paper explicitly states that a 30% improvement in MRSS constituted a clinically meaningful response.
This threshold was not created after the fact. It was the authors’ own predefined benchmark for success.
What the Data Actually Show
When the trial data are analyzed appropriately—focusing on patients who completed therapy and using the authors’ stated outcome measures—the results demonstrate that:
- The minocycline treatment cohort achieved a mean MRSS improvement exceeding 30%
- This improvement met and surpassed the trial’s own predefined criterion for clinical success
- The magnitude of improvement was comparable to or greater than contemporaneous systemic sclerosis trials of accepted immunosuppressive therapies
Despite this, the study was published and subsequently cited as negative, with conclusions that did not reflect the outcome thresholds specified in the methods. They even made the firm conclusion that no further research should be conducted, another violation of scientific publication standards.
Key Concerns Raised in the Ethics Complaint
The Road Back Foundation’s complaint and retraction request outline several core issues:
- Misrepresentation of Outcomes
The published conclusions do not align with the authors’ predefined success criteria, creating a misleading characterization of the results.
- Inappropriate Interpretation of Completion Data
Patients who completed therapy and demonstrated meaningful clinical improvement were not adequately represented in the study’s final interpretation.
- Failure to Contextualize Clinical Significance
The observed MRSS improvements meet standards widely accepted as clinically meaningful in systemic sclerosis research, yet this significance was not acknowledged.
- Lasting Harm to Patients and Scientific Discourse
For over 20 years, this study has been used to dismiss a low-cost, generally well-tolerated therapy—potentially limiting treatment options for patients with a life-altering disease.
What RBF Is Requesting
RBF is not calling for the suppression of data, but for scientific correction and transparency. Specifically, we have requested that the journal:
- Conduct an independent review of the study’s methodology, outcomes, and conclusions
- Issue a correction or retraction acknowledging that the minocycline cohort met the predefined success threshold
- Ensure the medical record accurately reflects the study’s actual findings
Correcting the record does not mandate clinical adoption of any therapy—but it does ensure that future decisions are made using accurate interpretations of published data.
Why This Matters Now
Medical science evolves through reassessment, replication, and correction. When errors or mischaracterizations persist unchallenged, they can harden into dogma, to the detriment of patients and progress alike.
At a time when drug repurposing, antimicrobial-immune interactions, and low-toxicity therapies are receiving renewed attention, it is especially important to revisit influential studies that shaped earlier conclusions.
Patients with systemic sclerosis deserve access to accurate information, honest interpretation of evidence, and open scientific dialogue.
A Commitment to Integrity and Patients
The Road Back Foundation’s mission has always been to advocate for patients through education, research, and integrity in science. Filing this ethics complaint is a continuation of that mission.
We believe that correcting the scientific record—where warranted—is not adversarial. It is a responsibility shared by researchers, journals, clinicians, and advocates alike.
We will continue to update the community as this process unfolds.
References
Mayes MD, et al. Minocycline in Systemic Sclerosis. Arthritis & Rheumatology. 2004.
If you or a loved one has been affected by this misinformation, please consider making a contribution to The Road Back Foundation so we can continue or efforts to educate the public and medical professionals on this potentially life-saving treatment. Click Here to Donate Now.